Earnings Call Intelligence Subscribe
Home › Call Sheets › MRNA › Q1'26
Call sheet · Q1'26

Moderna (MRNA)

Q1'26 earnings call · held May 1, 2026 · compared with the Q4'25 call · management-credibility review
9/12
Disclosure score
2 medium, 5 low flags
Financial quality
Bottom line
The sleeper story is strategic partnerships - UK/Canada/Australia deals drove $300M revenue jump while everyone fixates on COVID market declines. The obvious headline is flu vaccine rejection, but the real story is Europe reopening in 2027 with world's first combo vaccine already approved. The binding constraint isn't demand or manufacturing - it's regulatory unpredictability that creates investment hesitation. Bancel nailed it: 'When expectations and review timelines are unpredictable, companies face greater risk and can hesitate to invest.' My view changes if partnerships fail to deliver contracted minimums or if European pricing disappoints versus expectations.

The 30-second version

  • SLEEPER STORY: Strategic partnerships quietly becoming the growth engine while everyone obsesses over COVID market declines
  • Flu rejection creates Arbutus settlement overhang, but Europe/international approvals proceeding
  • Intismeran monotherapy pivot signals confidence in safety profile, but Phase III interim timing remains vague

What changed this quarter

MetricQ4'25Q1'26Change
Total Revenue$700M (Q4 2025, down from $1.9B FY)$400M (Q1 2026, up from $100M Q1 2025)+300% YoY driven by international partnerships
International Revenue Mix57% ($400M of $700M Q4)80% ($320M of $400M Q1)Geographic shift toward partnership revenues
Cost of Sales$868M FY 2025 (41% decrease YoY)$77M ex-settlement (Q1, 14% decrease YoY)Underlying improvement excluding $878M Arbutus charge
R&D Expenses$3.1B FY 2025 (31% decrease YoY)$649M Q1 (24% decrease YoY)Continued clinical wind-down, but Phase III programs advancing
SG&A Expenses$1B FY 2025 (13% decrease YoY)$173M Q1 (18% decrease YoY)Cost discipline accelerating
Net Loss$2.8B FY 2025 vs $3.6B FY 2024$500M ex-settlement Q1 (vs $1B Q1 2025)50%+ improvement in underlying losses
Cash and Investments$8.1B end of 2025$7.5B end Q1 2026$600M decrease from operations, settlement not yet paid
Adjusted Cash Costs$4.3B FY 2025 vs $5.5B guidance$4.2B target for FY 202626% YoY reduction Q1, on track for full year
Revenue Growth GuidanceUp to 10% for 2026 (from Q4 call)Reiterating up to 10% for 2026Maintained despite flu setback
Geographic Revenue Split Guidance50/50 US/International expected 202650/50 US/International maintainedPartnership revenues offsetting US market challenges

Accountability tracked

8 new promises made5 narrative shifts flagged8 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full MRNA Q1'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.